Review article

https://doi.org/10.2478/v10007-010-0039-2

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses

SEPTIMIU BUCURESCU orcid.org/0000-0002-5333-9361 ; “Rhoen Klinikum AG” Hospital, 97616 Bad Neustadt ad Saale, Germany

Abstract

Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.

Keywords

cancer therapies; Herpes simplex virus type 1 glycoproteins E and I; antibody mediated neutralization of oncolytic viruses

Hrčak ID:

59808

URI

https://hrcak.srce.hr/59808

Publication date:

1.12.2010.

Article data in other languages: croatian

Visits: 2.043 *